Phase 2 study of Pemetrexed + Carboplatin + Bevacizumab as first line therapy for nonsquamous non-small cell lung cancer with EGFR Mutation (CJLSG0910)
Not Applicable
- Conditions
- Advanced non-squamous non-small cell lung cancer with EGFR Mutation
- Registration Number
- JPRN-UMIN000003737
- Lead Sponsor
- Central Japan Lung Study Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 32
Inclusion Criteria
Not provided
Exclusion Criteria
1) Brain metastasis 2) Hemoptysis (>=2.5ml) 3) Active infection 4) Fever 5) Serious disease condition 6) Active double cancer 7) Cavity fluid retention difficult to control 8) Severe drug allergy 9) Receiving anticoagulant drug (except Aspirin under 325mg/day) 10) Active GI bleeding or inflammation in the abdominal cavity. 11) Pregnancy or lactation 12) Patients whose participation in the trial is judged to be inappropriate by the attending doctor
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Response rate
- Secondary Outcome Measures
Name Time Method Safety Disease control rate Overall survival Progression free survival